Virksomhedsform
Aktieselskab
Etableret
1984
Størrelse
Mellemstore
Ansatte
70
Omsætning
1.061 MDKK
Bruttofortj.
121 MDKK
Primært resultat (EBIT)
21 MDKK
Årets resultat
14 MDKK
Egenkapital
95 MDKK
annonce

Flere nøgletal og analyser?

Med en Bisbase Premium konto får du flere nøgletal for både virksomheder, koncerner og brancher samt adgang til eksklusive brancher indeholdende virksomheder nøje sammensat af eksperter. Og vil du lave dine egne analyser kan du også det! Det tager få minutter at få adgang - og det behøver ikke at koste dig noget!

Rang Årets resultat

Rang i branche
49/444
"Top 35%"
Rang i Danmark
9.357/342.443
"Top 10%"

Direktion top 3

Bestyrelse top 3

Vatroslav Mateljic 1Bestyrelsesformand
Jesper Lindahl 1Bestyrelsesmedlem
Christian Ramskov 1Bestyrelsesmedlem

Legale ejere top 3

Tegningsregler

Selskabet tegnes af en direktør, af tre medlemmer af bestyrelsen i forening, af bestyrelsens formand og et andet medlem af bestyrelsen i forening eller af den samlede bestyrelse.  

Stamoplysninger baseret på CVR

NavnTakeda Pharma A/S
BinavneAb Pharma A/S, Basoderm A/S, Benzon Bio-Tech A/S, Benzon Biosystems A/S, Benzon Pharma A/S, Dak Laboratories A/S, Danimed A/S, Nettopharma A/S, Nycomed Benzon A/S, Nycomed Consumer A/S, Nycomed Dak A/S, Nycomed Danmark A/S, Nycomed Dk A/S, Nycomed Pharma A/S, Nycomed Pharma-Medica A/S, Pharma-Medica A/S, Pharmachemie A/S, Shire Denmark A/S, Takeda Pharmaceuticals Denmark A/S, Ab Pharma Aps, Basoderm Aps, Benzon Bio-Tech Aps, Benzon Biosystems Aps, Benzon Pharma Aps, Dak Laboratories Aps, Dak-Laboratoriet A/S, Danimed Aps, Nycomed A/S, Nycomed Aps, Nycomed Benzon Aps, Nycomed Dak Aps, Nycomed Dk Aps, Nycomed Pharma Aps, Nycomed Pharma-Medica Aps, Pharma-Medica Aps, Takeda Pharmaceuticals Denmark Aps Vis mere
CVR16406899
AdresseDelta Park 45, 2665 Vallensbæk Strand
BrancheEngroshandel med medicinalvarer og sygeplejeartikler [464610]
Etableret02-01-1984 (40 år)
Første regnskabsperiode02-01-1984 til 31-12-1984
VirksomhedsformAktieselskab
Antal ansatte72 (årsværk:65)
ReklamebeskyttelseNej
RevisorKpmg P/S siden 20-11-2014
Regnskabsperiode01-04 til 31-03
Selskabskapital10.100.000 DKK
10.000.000 DKK (30-03-2019 - 31-03-2020)
956.100.000 DKK (16-03-2016 - 29-03-2019)
810.100.000 DKK (23-12-2014 - 15-03-2016)
810.000.000 DKK (08-11-2012 - 22-12-2014)
809.000.000 DKK (19-06-2012 - 07-11-2012)
Vedtægter seneste25-04-2023

Formål

Selskabets formål er udvikling og fremstilling af samt handel med lægemidler og hermed beslægtede varer.

Regnskab

 202320222021
Valuta/enhed000' DKK000' DKK000' DKK
Omsætning
1.061.206
+17%
910.058
-53%
1.939.231
+24%
Bruttofortjeneste
120.582
-22%
153.989
-86%
1.134.904
-64%
Årets resultat
13.573
-57%
31.795
-95%
667.744
-75%
Egenkapital
94.892
+17%
81.238
-92%
1.046.401
-61%
Balance
485.750
-22%
622.293
-69%
2.017.020
-47%

Ledelsesberetning

Management’s Review

Development in the yearThe income statement of the Company for 2022/23 shows a profit of DKK 24,222k, and at 31 March 2023 the balance sheet of the Company shows equity of DKK 105,541k.The past year and follow-up on development expectations from last yearOperating profit for the year is in line with the expectations and there has not been any major single events influencing the result.Operating risks and financial risksOperating risksManagement teams in Takeda Pharma A/S as well as the Group are responsible for monitoring and assessing potential business risks that may arise.The Company's activities are subject to rigorous regulatory control and approval procedures. Moreover, the ongoing cost management by public authorities and the health sector will result in lower prices and reimbursements in the future. Management continuously monitors the development and assesses the effect.Future growth and success will depend on Takeda's ability to develop new products and the local companies' ability to market these products. Moreover, the development of sales in the existing product portfolio will be essential to the financial performance of Takeda Pharma A/S.Credit risksThe financial risks of Takeda Pharma A/S are administered in accordance with the policies and instructions adopted by the Group. Accordingly, credit risks and outstanding payments are evaluated continuously.Financial risks are administered centrally in the Group. The Group does not carry out financial transactions that are not related to hedging of the underlying business risks. It is thus not the Group's policy to engage in active speculation in financial risks.Targets and expectations for the year aheadThe company expects the underlying profit in the financial year 2023/24 on the same level as the financial year 2022/23.
19-09-2023

Kort